In a HepG2 cell culture model of NASH, exenatide ameliorated NASH via the inhibition of pyroptosis, which was demonstrated by reduced levels of its mediator molecules, such as nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), caspase-1, and IL-1β, resulting in the significant improvement of NASH [75]. The gene discussed is CASP1; the disease is metabolic dysfunction-associated steatohepatitis.